MRKR Marker Therapeutics Inc: שווי עסקי להכנסות

Strong capital and a staff of top immunologists enable Marker Therapeutics (MRKR) to advance cell therapy. The company's current price-to-sales ratio on this GURU.Markets platform chart confirms asset movement, where the 11445.45 metric serves as the target level. Future growth is based on the commercialization of the MultiTAA system, while the development strategy relies on R&D alliances with clinics without resorting to external acquisitions.
פילוחי מדדים פיננסיים ומדדי שוק עבור Marker Therapeutics, Inc. (MRKR)

This metric determines the market value of the business minus net debt relative to sales volume, allowing the investor to assess the efficiency of revenue capitalization without the influence of debt load. The current enterprise value-to-revenue ratio of 11445.45 reflects market expectations for the expansion of the oncology center network and the exclusivity of the orphan status of Marker Therapeutics (MRKR) drugs in leukemia therapy.